Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksParity Regulatory News (PTY)

Share Price Information for Parity (PTY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.925
Bid: 0.85
Ask: 1.00
Change: 0.00 (0.00%)
Spread: 0.15 (17.647%)
Open: 0.925
High: 0.925
Low: 0.925
Prev. Close: 0.925
PTY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

HoT regarding revenue share on AI data platform

13 Nov 2019 07:00

RNS Number : 1793T
Parity Group PLC
13 November 2019
 

 

13 November 2019

AIM: PTY

 

Parity Group PLC

 

("Parity" or "Company")

 

Parity shares revenue with Integumen plc to deliver AI data platform solutions to clients

 

Parity announces that it has signed Heads of Terms with Integumen plc to enter a multi-year Framework Agreement ("Agreement") to be completed on or before the 18th of December 2019. It is envisaged that the Agreement will give Parity access to Integumen's Artificial Intelligent ("AI") software which it can supply across its client base which includes the National Health Service ("NHS"), Central Government and Private Institutional clients.

 

This Agreement accelerates Parity's transformation from a predominately commoditised recruitment business to a data consultancy service provider of intelligent data management systems, extracting value using analytics, with a focus on return on investment for our Company's 100+ institutional clients. The software includes full GDPR compliance with secure cloud data migration from existing legacy systems to a digital workplace through the military grade encryption "Drive4Growth" AI platform powered by Integumen's Rinodrive.

 

Combined benefits:

·; Recurring shared revenue streams for both Parity and Integumen in 2020

·; Value-added proposition in demand from Parity clients with c. 3 to 5-year annual contracts

·; Immediate access to 100+ public and private institutional clients

·; Trusted approved vendor for Government and private sectors for over 45 years

·; 700+ data experts and 50+ enterprise sales and office professionals

·; Existing cross-over access to educational institutional research facilities

·; Access to multiple industry, public and private sector distribution routes to market

·; Well defined roadmap to next level business growth for both Parity and Integumen

 

Since the appointment of the new CEO, in February 2019, there has been structural changes to the business. Client management focus is on increasing profitability. New senior management has reduced high-volume low-margin business to low-volume high-margin multi-line business development. This includes new, higher value data expert professional service offerings. Reduction in headcount of 35% has resulted in a rolling 12-month gross cost saving of £2m. Heading into 2020 with these changes and with today's agreement, the board expect the Company will deliver a right-sized company with higher margins, increased profitability leading to improved shareholder value.

 

Matthew Bayfield, CEO of Parity Group plc, comments:

"Parity is pleased to be partnering with Integumen and rolling out the Drive4Growth AI platform to our client base. We have been working with many of the same clients for 45 years, so we understand their needs. With healthcare sector data in 2020 expected to double every 73 days, our clients need to securely manage and extract greater value using analytics and AI in order to make important decisions. The Drive4Growth AI platform delivers on those requirements, increases revenue per client, increases client contract term and generates a higher margin, leading to greater profitability."

 

Gerard Brandon, CEO of Integumen plc, comments:

"We are delighted to be able to roll-out the Drive4Growth AI platform in partnership with the credibility and reputation that Parity data experts hold with an extensive list of public and private institutions. We look forward to working alongside Parity to extract greater value for their clients and contribute to the transformation of the UK's National Health Service, public and private institution data over the next few years."

 

Certain information contained in this announcement would have constituted inside information (as defined by Article 7 of Regulation (EU) No 596/2014) ("MAR") prior to its release as part of this announcement and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

 

Contacts

 

Parity Group plc

Matthew Bayfield, CEO

Roger Antony, GFD

+44 (0) 208 543 5353

WH Ireland Limited

(Nominated Adviser & Broker)

 

Mike Coe

Chris Savidge

+44 (0) 117 945 3470

Donhead Consultants (Broker)

David Beck

+44 (0) 7836 293 383

 

About Parity Group: www.parity.net

Parity helps organisations find the right people, skills and data to support data-led business decisions. Providing advice on data and with access to qualified personnel with skills offered, either as a managed service, through resourcing in the contract or permanent market or as part of a learning and development programme.

Income derives from a mix of long-term contracts with public and private sector organisations as well as expanded projects with existing clients as a result of strong relationships and a track record of high client satisfaction. Key highlights comprising of:

·; Over 45 years of expertise in public and private recruitment and service contract sector

·; More than 50 employees across the UK

·; Client numbers exceed 100 in both UK and Ireland

·; Associate numbers supporting client services exceeds 700

 

About Integumen: www.integumen.com

Integumen is a vertically integrated product and services company for skin related diseases, treatments and therapies with four business units:

 

·; Labskin AI's technology platform incorporates artificial intelligence within clinical research for medical device, pharmaceuticals, cosmeceuticals and related life science test services. Labskin allows skincare, healthcare, pharmaceutical manufacturers and cosmetic companies to test their products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies.

·; Rinodrive is a data aggregation, refining and AI analysis open-source eco-system designed to provide third-party service providers the ability to offer their clients valuable insights that support clinical, operational and financial decisions in healthcare services, third-level education, government departments and the financial sector.

·; Wound pHase is developing skin and wound care products using its proprietary wound dressing technology. Working in collaboration with CBD providers creating a CBD infused diabetic wound care product range.

·; Stoer-for-men skin products e-commerce division offers a range of skincare products derived from 5 natural super-ingredient plant extracts specifically for men to reduce the signs of ageing and is also used as a control for client testing within Labskin laboratories.

 

RinoDrive "Drive4Growth": www.rinodrive.com

A fully integrated set of software tools that can ingest data, in any volume, from any source in any format, interact with it, learn from it and enrich it to unlock insights and discoveries.

This data management solution was developed by scientists and engineers with experience in software, sensors, AI, optofluidic research, fintech, green-tech, travel and healthcare.

It was designed to allow interaction, in a cyber-secure environment, with commercially sensitive data, and to share insights across multi-disciplinary teams, generating different data formats, from multiple sources, located in different countries.

RinoDrive delivers big data, AI functionality and world class infrastructure to large companies with big data problems. These include financial services, education and life science companies. Most recently completing the automation of laboratories and application of AI to unearth more knowledge about the skin microbiome. This led to the acquisition in May 2019 by Integumen PLC, to secure access to, and the exploitation of data from some of the largest cosmetic, pharmaceutical and medical companies in the world.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AGRFFIFWEFUSEFF
Date   Source Headline
15th Apr 20247:00 amRNSHolding(s) in Company
5th Apr 20243:41 pmRNSHolding(s) in Company
13th Mar 20245:59 pmRNSHolding(s) in Company
13th Mar 20245:00 pmRNSReceipt of Final Consideration
1st Feb 20243:10 pmRNSHolding(s) in Company
25th Jan 20247:00 amRNSHolding(s) in Company
19th Dec 202310:59 amRNSHolding(s) in Company
8th Dec 20232:31 pmRNSCompletion of Disposal, Change of Name & Website
7th Dec 20235:07 pmRNSResult of General Meeting
21st Nov 20232:43 pmRNSProposed disposal of PPL and notice of GM
29th Sep 20237:00 amRNSInterim Results
4th Aug 20237:00 amRNSTrading Statement
15th Jun 20234:05 pmRNSResult of AGM
15th Jun 20237:00 amRNSAGM Statement
22nd May 20237:00 amRNSAnnual Report & Accounts and Notice of AGM
16th May 20237:00 amRNSFinal Results
26th Jan 20237:00 amRNSDirectorate Change
26th Jan 20237:00 amRNSTrading Update
30th Dec 20227:00 amRNSSale and Licence of Trademark
29th Sep 20227:00 amRNSInterim Results
25th Jul 20227:00 amRNSTrading Update
20th Jun 20222:20 pmRNSHolding(s) in Company
8th Jun 20221:24 pmRNSResult of AGM
8th Jun 20227:00 amRNSAGM Statement
16th May 20227:00 amRNSPosting of Annual Report and Notice of AGM
12th May 20227:00 amRNSChange of Adviser
9th May 20227:00 amRNSDirector Dealing
27th Apr 20227:00 amRNSFinal Results
20th Jan 20227:00 amRNSTrading Update
4th Nov 20217:00 amRNSDirector/PDMR Shareholding
13th Oct 20217:00 amRNSContract award
4th Oct 20217:00 amRNSGrant of Warrants and Options to Directors/PDMRs
22nd Sep 20218:41 amRNSInvestor Presentation
22nd Sep 20217:00 amRNSInterim Results
26th Aug 202110:40 amRNSTrading Update
24th Jun 202112:00 pmRNSIssue of Equity, Option Grant & Director Shares
10th Jun 202112:15 pmRNSResult of AGM
9th Jun 20212:40 pmRNSDirectorate Change
18th May 202111:18 amRNSNotice of AGM and Posting of Accounts
4th May 20219:50 amRNSHolding(s) in Company
21st Apr 20217:00 amRNSDirectorate Change
21st Apr 20217:00 amRNSFinal Results
12th Apr 20217:00 amRNSChange of Adviser
1st Mar 20217:00 amRNSNew contract wins and Notice of Results
1st Feb 20217:00 amRNSContract win
28th Jan 20217:00 amRNSTrading Statement
25th Nov 20207:00 amRNSDirector/PDMR Shareholding - Options Grant
22nd Sep 20207:00 amRNSInterim results
3rd Sep 20207:00 amRNSFramework Agreement and Notice of Interim Results
27th Aug 202011:41 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.